Columbia Laboratories revenues boost 11 percent to $32.

, today announced monetary results for the three – and twelve-month periods ended December 31, 2014. During this transitional season we restarted our drug development activities, strengthened our management team significantly, and generated a substantial amount of cash, mentioned Frank Condella, CEO. We look forward to initiating the Stage II research of COL-1077, a lidocaine bioadhesive gel meant as an acute use anesthetic for minimally invasive gynecological methods, in the second quarter of 2015. In addition, we are close to finalizing our scientific advisory board, that will support our experienced team in evaluating other brand-new product candidates in ladies's health.The Phase II scientific trials possess concluded. BI10773 blocks renal glucose absorption in the kidneys, thus raising urinary excretion of glucose and therefore improving glycaemic control. The inhibition of SGLT-2 has been noticed to possess a positive impact on bodyweight loss and decrease in blood circulation pressure. About Boehringer Ingelheim The Boehringer Ingelheim group is among the world’s 20 leading pharmaceutical businesses. Headquartered in Ingelheim, Germany, it globally operates, with 142 affiliates in 50 countries and a lot more than 41,500 employees.